treatment of choice for EGUS is omeprazole, a proton pump inhibitor available as a proprietary oral formulation. Empirical administration of omeprazole without diagnostic evidence of gastric disease is commonplace in equine practice. In people, proton pump inhibitors have been associated with the development of infectious gastrointestinal complications and a shift in gastrointestinal microflora. An increase in the incidence of diarrhea has been reported in foals treated with proton pump inhibitors. Novel sequencing technologies have allowed indepth analysis of broad microbial communities, including those present in the gastrointestinal tract.
Objectives: The objective of this study was to determine the effect of administration of omeprazole on the fecal microbiota of healthy adult horses.
Methods: Twelve horses were randomly assigned to either treatment (proprietary omeprazole paste) or placebo (water) groups. Administration of treatment or placebo occurred daily for twenty-eight days. Fecal samples were collected prior to initial treatment (day 0), and on days 7, 28, 35, and 56. 16S rRNA gene sequences were amplified and sequenced from DNA extracted from each fecal sample to characterize diversity and structure of the fecal microbiota.
Results: Composition and diversity of the fecal microbiota were not significantly different between the treatment and placebo groups or over time.
Conclusions: Omeprazole administration does not have a measurable effect on the fecal microbiota diversity in healthy adult horses. Background: Probiotic use is widespread in the equine industry, yet there is little data assessing the impact of probiotics on the gastrointestinal microbiome and metabolome. This study attempts to investigate the influence of probiotics on the equine gastrointestinal metabolome using an antibiotic challenge model.
Objectives:
The objective of this study was to evaluate the role of an equine prebiotic/probiotic supplement (Platinum Balance â ) on Lactobacillus spp. quantification and the metabolome following antibiotic challenge.
Methods: A randomized crossover design was applied to 5 horses undergoing 4 treatment periods consisting of: no treatment, antibiotics alone (Excede â ), probiotics alone (Platinum Balance â ), and both antibiotics and probiotics. Each treatment period was 14 days and included fecal samples acquired per rectum on days 0, 3, 10, and 14 to undergo microbial and metabolomics analysis. Statistical analysis included principle component analysis (PCA), analysis of variance (ANOVA), mixed model ANOVA, and supervised metabolic profiling using OPLS discriminant analysis.
Results: No significant differences were detected in Lactobacillus spp. quantitation between or within horses in response to treatment. Metabolomics data demonstrated statistically significant changes in multiple compounds in which the response to treatment is time dependent. OPLS-DA revealed some distinct separations between fecal metabolic features between treatment groups at day 14 suggesting that probiotic administration has a significant impact on fecal metabolites and these metabolites more closely resemble those of control samples compared with antibiotic treatment alone.
Conclusion:
Antibiotics alter the fecal metabolome. Administration of probiotics in conjunction with antibiotics may help to normalize the fecal metabolome.
